Evidence map›Paper›PMID 27536067›Full record

ArticleDrug design, development and therapy2016

Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.

Marina Pinheiro, Ricardo Ribeiro, Alexandre Vieira, Fernanda Andrade, Salette Reis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Masculinization of Red Tilapia (Animals : an open access journal from MDPI · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marina PinheiroIUCIBIO, REQUIMTE, Chemistry Department, Faculty of Pharmacy.
Ricardo RibeiroIUCIBIO, REQUIMTE, Chemistry Department, Faculty of Pharmacy.
Alexandre VieiraIUCIBIO, REQUIMTE, Chemistry Department, Faculty of Pharmacy.
Fernanda AndradeLaboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.
Salette ReisIUCIBIO, REQUIMTE, Chemistry Department, Faculty of Pharmacy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work aimed to design, develop, and characterize a lipid nanocarrier system for the selective delivery of rifabutin (RFB) to alveolar macrophages. Lipid nanoparticles, specifically nanostructured lipid carriers (NLC), were synthetized by the high-shear homogenization and ultrasonication techniques. These nanoparticles were designed to exhibit both passive and active targeting strategies to be efficiently internalized by the alveolar macrophages, traffic to the acidified phagosomes and phagolysosomes, and release bactericidal concentrations of the antituberculosis drug intracellularly. NLC that could entrap RFB were prepared, characterized, and further functionalized with mannose. Particles' diameter, zeta potential, morphology, drug% entrapping efficiency, and drug release kinetics were evaluated. The mannose coating process was confirmed by Fourier transform infrared. Further, the cytotoxicity of the formulations was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay in A549, Calu-3, and Raw 264.7 cells. The diameter of NLC formulations was found to be in the range of 175-213 nm, and drug entrapping efficiency was found to be above 80%. In addition, high storage stability for the formulations was expected since they maintained the initial characteristics for 6 months. Moreover, the drug release was pH-sensitive, with a faster drug release at acidic pH than at neutral pH. These results pose a strong argument that the developed nanocarrier can be explored as a promising carrier for safer and more efficient management of tuberculosis by exploiting the pulmonary route of administration.

Indexed as

Drug CarriersNanoparticlesAnimalsAntibiotics, AntitubercularCell Line, TumorCell SurvivalDrug CompoundingDrug StabilityHumansHydrogen-Ion ConcentrationKineticsLectins, C-TypeLigandsLipidsMacrophages, AlveolarMannoseAntibiotics, AntitubercularDrug CarriersLectins, C-TypeLigandsLipidsMannoseMannose-Binding LectinsMannose ReceptorReceptors, Cell SurfaceRifabutindrug delivery systemslipid nanoparticlesmannosenanostructured lipid carriersrifabutintuberculosis

Identifiers

PMID27536067
PMCPMC4977088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.